Table 2.
Prevalence of Risk Factors and Nodal Disease
|
All (n=123) |
No Nodal Disease (n=92) |
Nodal Disease (n=31) |
Prevalence of Nodal Disease (%) |
||
|---|---|---|---|---|---|
| Tumor size by CT (%) | |||||
| ≤3cm | 72 (59%) | 64 (70%) | 8 (26%) | 11% | |
| >3–7cm | 45 (38%) | 25 (27%) | 20 (65%) | 44% | |
| >7cm | 6 (4.9%) | 3 (3.0%) | 3 (10%) | 50% | |
| Central tumor location | |||||
| Primary study definition (%) | 63 (51%) | 40 (43%) | 23 (74%) | 37% | |
| ACCP definition (%) | 51 (42%) | 29 (32%) | 22 (71%) | 43% | |
| NCCN definition (%) | 62 (50%) | 39 (42%) | 23 (74%) | 37% | |
| SUVMax primary tumor | |||||
| Quartile 1 (0.80–3.50) | 32 (26%) | 31 (34%) | 1 (3.2%) | 3.1% | |
| Quartile 2 (3.60–7.10) | 31 (25%) | 27 (29%) | 4 (13%) | 13% | |
| Quartile 3 (7.20–13.5) | 30 (24%) | 18 (20%) | 12 (39%) | 40% | |
| Quartile 4 (13.6–44.9) | 30 (24%) | 16 (17%) | 14 (45%) | 47% | |
| Lymphadenopathy (%) | |||||
| N0 | 80 (65%) | 69 (75%) | 11 (36%) | 14% | |
| N1 | 25 (20%) | 9 (9.8%) | 16 (52%) | 64% | |
| N2 | 31 (25%) | 18 (20%) | 13 (42%) | 42% | |
| N3 | 3 (2.4%) | 2 (2.2%) | 1 (3.2%) | 33% | |
| N1–3 | 43 (35%) | 23 (25%) | 20 (65%) | 47% | |
|
FDG-uptake by hilar/ mediastinal nodes (%) |
|||||
| N0 | 69 (56%) | 60 (65%) | 9 (29%) | 13% | |
| N1 | 47 (38%) | 27 (29%) | 20 (65%) | 43% | |
| N2 | 32 (26%) | 16 (17%) | 16 (52%) | 50% | |
| N3 | 10 (8.1%) | 7 (8%) | 3 (10%) | 30% | |
| N1–3 | 54 (44%) | 32 (35%) | 22 (71%) | 42% | |
| Plasma levels VEGF-C (pg/mL) | |||||
| Quartile 1 (106–329) | 31 (25%) | 22 (24%) | 9 (29%) | 30% | |
| Quartile 2 (340–530) | 31 (25%) | 24 (26%) | 7 (23%) | 23% | |
| Quartile 3 (543–865) | 31 (25%) | 25 (27%) | 6 (19%) | 19% | |
| Quartile 4 (868–3,796) | 30 (25%) | 21 (23%) | 9 (29%) | 30% | |
Non-small cell lung cancer (NSCLC), ACCP (American College of Chest Physicians), NCCN (Nacional Comprehensive Cancer Network), Maximum standard uptake value (SUVMax), fluorodeoxygluose (FDG), Vascular endothelial growth factor-C (VEGF-C).